Your Product Launch Just Started Your Pharmacovigilance Clock

Congrats! You made it to launch week. Your team was staffed up and ready to handle dosing questions, prior-authorization headaches, and the first “is this normal?” calls from patients who just picked up a prescription that didn’t exist for them a month ago. Everyone braced for volume, but fewer teams are ready to handle what that volume is made up of.

Somewhere in that first wave of calls is a patient describing something nobody flagged in training, because nobody could have. And it wasn’t because anyone missed a step. Rather, it’s likely that the population calling in this week was never the population your trial was built to test.

Trials feel clean and controlled, but product launches look more like the wild west. And the shift from one to the other isn’t a customer-support ramp-up — it’s the first real stress test of your pharmacovigilance process, arriving before you have any track record to lean on.

The new signals showing up at launch aren’t a gap in oversight. They’re what happens when a population gets bigger and less curated than any trial could be.

What Launch Introduces Immediately

Approval removes the guardrails that made the trial legible, and it does it all at once.

Off-label use begins immediately, and so do drug interactions nobody modeled, because the drug is now being taken alongside whatever else a given patient is already on. The population using it is older, younger, and sicker than the trial’s inclusion criteria allowed. Comorbidities that would have excluded someone from the study are now just part of who’s calling in. And adherence is no longer something anyone is tracking. Patients skip doses, take two at once to catch up, or time them around a meal rather than a schedule, and none of it gets flagged unless someone happens to mention it.

This isn’t a slow drift. It’s immediate, and it hits at the moment your pharmacovigilance capture process has the least precedent to draw on.

Where These New Signals Actually Surface First

These signals surface first in ordinary conversations: a refill request, a billing question, a “when should I expect this to kick in?” They show up long before anything reaches a formal adverse event report. Somewhere in the patient’s own words is something that’s never been categorized before, because this particular combination of drug, comorbidity, dose, and duration hasn’t existed in a patient population until now.

The agent taking that call has no “usually this means X” to draw on. There’s no pattern to recognize, because there’s no history of similar calls to have built one from. This may also be the first time anyone has described this particular experience.

That’s where the pharmacovigilance work actually starts for a new product. It starts in a live conversation, not in a safety database. The agent handling that conversation is doing the job correctly and still has no way of knowing that what they just heard matters.

Detection Can’t Depend on Someone Recognizing the Unfamiliar

Capturing safety events consistently, and at scale, can’t rely solely on call center agents recognizing something there’s no precedent for. No agent, however well-trained, can be expected to catch what they’ve never seen before — and a reportable event shouldn’t need to look familiar to get caught.

Detection has to work the same way whether the event is common or brand new — flagged because of what’s actually being described, not because someone in a call center has heard something like it before. That consistency is exactly what’s missing when the population outgrows the pattern library your team built during the trial, and it’s what a launch demands from day one, before anyone’s had the chance to build one.

Pharmacovigilance Can’t Wait for Volume to Arrive

Safety events don’t wait for a team to get its footing. Regulators expect serious, unexpected cases to be reported within days of being identified, even in the first week after launch. Yet only roughly 1% of serious and unexpected adverse drug reactions are estimated to reach the FDA at all. That gap is widest when a population is least understood, which is exactly what launch is.

Patient support teams will hear these events firsthand, but hearing an event isn’t the same as catching it. Some will go unrecognized and never reach pharmacovigilance. Other times, non-events will be flagged out of caution, leaving the safety team to dig through noise for the few cases that matter. The population calling in during launch week is one your trial was never built to test, so your safety team needs accurate detection across those conversations from the start.

See how Authenticx gives your safety team visibility into patient conversations from day one of launch.